Cat. No. | Product Name | Target | Signaling Pathways |
---|---|---|---|
T23371 |
SMER3
SMER 3 |
Others; Ligand for E3 Ligase | Others; PROTAC |
SMER3 是选择性的 Skp1-Cullin-F-box (SCF)Met30泛素连接酶抑制剂。SMER 3 通过抑制 SCFMet30来增强 Rapamycin 的生长抑制作用。 | |||
T72043 |
SCFSkp2-IN-2
|
Apoptosis; E1/E2/E3 Enzyme | Apoptosis; Ubiquitination |
SCFSkp2-IN-2 是一种 Skp2抑制剂,其 KD 为 28.77 μM。AAA-237 诱导 NSCLC 细胞凋亡 (apoptosis),显示出抗肿瘤活性。 | |||
T3452 |
ISCK03
|
c-Kit | Tyrosine Kinase/Adaptors |
ISCK03 是一种特异性的 SCF/c-Kit 抑制剂。 | |||
T17065 |
TFMB-(R)-2-HG
|
Others | Others |
TFMB-(R)-2-HG 是一种具有细胞膜渗透性的 (R)-2-HG,急性髓细胞性白血病的致癌因子。它能够响应雌激素戒断损害 SCF ER-Hoxb8 细胞分化。 | |||
T3317 |
SZL P1-41
|
Apoptosis; Others; E1/E2/E3 Enzyme | Apoptosis; Others; Ubiquitination |
SZL P1-41 是 Skp2 抑制剂,可以阻止 Skp2-Skp1 复合物的组装。 它选择性地抑制 Skp2 SCF E3 连接酶活性,还在体内外抑制 Skp2 介导的 p27 和 Akt 泛素化。 它通过触发细胞衰老和抑制糖酵解来抑制 Y 细胞和 Y 干细胞的存活,有抗肿瘤作用。 | |||
T76919 | Barzolvolimab | ||
Barzolvolimab (CDX 0159)为人源化抗KIT IgG1单克隆抗体。其特异性地抑制KIT激活,有效降低慢性诱导性荨麻疹中皮肤肥大细胞数量及疾病活动程度。 | |||
T71654 |
APcK110
|
||
APcK110 is a novel Kit inhibitor . APcK110 inhibits proliferation of the mastocytosis cell line HMC1.2 and the SCF-responsive cell line OCI/AML3 in a dose-dependent manner . APcK110 is a more potent inhibitor of OCI/AML3 proliferation than the clinically used Kit inhibitors imatinib and dasatinib and at least as potent as cytarabine. APcK110 inhibits the phosphorylation of Kit, Stat3, Stat5, and Akt in a dose-dependent fashion, showing activity of APcK110 on Kit and its downstream signaling path... |